Merck upbeat on new data for MK-0524

Merck is sounding decidedly upbeat about the recent data on MK-0524, an experimental therapy for reducing flushing in patients with dyslipidemia. Flushing is an uncomfortable and common side effect associated with niacin and one of the primary reasons why patients stop taking the therapy. Dyslipidemia is a condition that disrupts the quantity of lipids in the blood. Merck is currently in Phase III with MK-0524A, a combination of MK-0524 and extended release niacin.

- here's the AFX report on the trial data 

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.